Floatz logo

2,4,6-OCTATRIENOIC ACID, 8-(3,4-DIHYDRO-1(2H)-NAPHTHALENYLIDENE)-3,7-DIMETHYL-, (2E,4E,6Z,8E)-

Non-melanoma Skin Cancer

University of Alabama at BirminghamSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

40 Active assets in the Non-melanoma Skin Cancer cohort.

Asset / SponsorPhaseRating
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
University of Alabama at Birmingham
Phase 4BB
Pembrolizumab
Essen Biotech
Phase 2BB
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB
gsk1120212
Cancer Research UK
Phase 2/3B
Nivolumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2B

View all 50 →

Same molecule, other indications

2,4,6-OCTATRIENOIC ACID, 8-(3,4-DIHYDRO-1(2H)-NAPHTHALENYLIDENE)-3,7-DIMETHYL-, (2E,4E,6Z,8E)- is also rated in:

breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
ductal breast carcinoma in situDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →